NewsUp one level
EuroNanoMed III - Joint Transnational Call for Proposals (2017) for “European Innovative Research & Technological Development Projects in Nanomedicine” open.
www.etpn2016.eu The next annual event of ETPN will be held from Wednesday, October 12 to Friday, 14 October 2016 in Heraklion (Greece) in collaboration with FORTH / IESL.
The recently established European Nanomedicine Characterisation Laboratory (EU-NCL) aims at providing critical infrastructure and characterisation services that are needed to analyse physical and chemical attributes, in vitro biological properties, and in vivo characteristics of emerging nanomedicines ready for translation and clinical trials.
The European Commission is seeking ideas for visionary technologies that can become the basis for future economic competitiveness and address societal challenges in Europe.
The ETPN and the EuroNanoMed II ERA-NET publish the Nanomedicine Strategic Research and Innovation Agenda to provide the ecosystem with a concrete framework, including priorities for research, and a long term vision up to 2030 to foster the fruitful deployment of innovative Nanomedicine solutions intended for healthcare.
The 1/2016 issue of the ETPN Newsletter is available!
Upcoming Deadline February 11th! The American National Cancer Institute Alliance for Nanotechnology in Cancer is currently working on an exciting new initiative - the Nanotechnology Start-Up Challenge in Cancer (NSC2). It is a joint effort between the Center for Advancing Innovation (CAI) and NCI.
European Technology Platform on Nanomedicine (ETPN) and ENATRANS announced during the BIO-Europe Conference, the winner projects of the Nanomedicine Award 2015.
Big data (in the areas of Alzheimer’s disease and blood cancers), medicines safety and respiratory disease are the focus of a €93 million Call for proposals launched by the Innovative Medicines Initiative (IMI). The two big data topics represent the first topics of the wider Big Data for Better Outcomes programme which was the subject of a consultation earlier this year. Further big data topics are already in the pipeline for future Calls for proposals. The Call is the sixth to be launched under the IMI 2 programme.
This page aims at providing basic information about the 2017 calls in Horizon 2020 that are of interest for the Nanomedicine community. It presents of course the Calls und the NMBP Work Programme but also further calls from different units or DGs.
This news aims at providing basic information about the current calls in Horizon 2020 that are of interest for the Nanomedicine community. It presents of course the Calls und the NMBP Work Programme but also further calls from different units or DGs.
A new job offer is available in the "Job Section"
Cristal Therapeutics starts clinical phase I trial with nanomedicine CriPec® docetaxel in patients with solid tumours
Maastricht, The Netherlands, September 29, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative drugs against cancer and other diseases, today announced the recent start of a clinical phase I trial with its lead candidate CriPec® docetaxel in patients with solid tumours. For this trial, patients are being recruited in two clinical centres in The Netherlands and in Belgium. The first trial data will be available in the course of Q2 2016.
The European Commission made public the final drafts documents to provide potential participants with the currently expected main lines of the work programmes 2016-2017. However, they are draft documents not yet finally endorsed by the Commission and their contents does not in any way prejudge the final decision of the Commission.
A US-Ireland partnership involving researchers at Queen’s University has been awarded £2.9m to develop new treatments for pancreatic cancer, which is the fifth most common cause of cancer deaths in the UK.
Find the right information and partners for the H2020 2016 Calls related to Nanomedicine
The Award winners will be presented at the BIO-Europe conference in Munich in November 2015.
The EU-funded consortium ENATRANS (Enabling Nanomedicine TRANSlation) launches the first Translation Advisory Board (TAB), a new instrument to provide free of charge advice and supports to ambitious international nanobiomedicine projects.
The call for suggestions for the European CTO of the Year 2015 is now open - who is the most inspiring, innovative and foresighted technology leader you know in Europe?
Last elections of the ETPN Executive Board (ExBo) took place in 2013, therefore new elections will be organised this year during the General Assembly of the ETPN, on 12th October 2015 in Dublin.
The ETPN released its Newsletter 2/2015, compiling internal news but also nanomedicine news, upcoming events, information on future calls...
The Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval.
The EuroNanoMed ERA-NET released a short clip on Regenerative Nanomedicine to promote the use of Nanoparticles for the regeneration of bone fractures and osteoporosis.
From the 22nd to the 23thd of June, the JRC hosted the first meeting of the national platforms on nanomedicine with 13 established European platforms.
The FP7 nanomedicine project NAMDIATREAM has been awarded best project during the EuroNanoForum which took place from June 10th to 12th in Riga.